Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant FOLFOXIRI vs CapeOX for Locally Advanced Rectal Cancer
NCT05201430Phase 3Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2021
- Primary completion
- Jun 2024
- Modality
- Nanoparticles, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 3 trial of fluorouracil, folinic acid, oxaliplatin, irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in rectal cancer, sponsored by Fudan University. Started Aug 2021; status: recruiting.
02
Drugs
fluorouracilfolinic acidoxaliplatinirinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05201430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05201430.